Randomized investigation of increased dialyzer membrane hydrophilicity on hemocompatibility and performance.

ABSTRACT:

Background

Hemodialyzers should efficiently eliminate small and middle molecular uremic toxins and possess exceptional hemocompatibility to improve well-being of patients with end-stage kidney disease. However, performance and hemocompatibility get compromised during treatment due to adsorption of plasma proteins to the dialyzer membrane. Increased membrane hydrophilicity reduces protein adsorption to the membrane and was implemented in the novel FX CorAL dialyzer. The present randomized controlled trial compares performance and hemocompatibility profiles of the FX CorAL dialyzer to other commonly used dialyzers applied in hemodiafiltration treatments.

Methods

This prospective, open, controlled, multicentric, interventional, crossover study randomized stable patients on post

SUBMITTER: Ehlerding G 

PROVIDER: S-EPMC11234537 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature